MedTrace Logo

Rizatriptan for Episodic Dizziness in Vestibular Migraine

NCT02447991 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 223

Last updated 2021-11-04

Study results available
· View outcomes & findings →

Summary

Suffering from dizzy spells and migraine headaches?

Vestibular Migraine (VM), a newly recognized type of migraine that causes bouts of dizziness.

University of California, Los Angeles (UCLA) and The Mayo Clinic is seeking people with VM to participate in a research study. The purpose of this study is to look at the natural history of VM and learn more about common symptoms. Investigators also want to learn the effects, both positive and negative, of the commonly used migraine drug, rizatriptan, when it is used for spells of dizziness in people with VM.

Patients may be eligible to participate if:

* Patients are between the ages of 18 \& 65
* Patients have a history of vestibular migraine
* Patients are able to maintain a vestibular symptom diary

The study includes 3 visits with compensation. All participants must complete questionnaires on dizziness, headache symptoms, general health and well-being, mental health, and a questionnaire on patient's satisfaction with study medication.

Conditions

  • Vestibular Migraine
  • Migrainous Vertigo

Interventions

DRUG

Rizatriptan

During the study either placebo or Rizatriptan will be given to subjects to take during the treatment phase of this study.

DRUG

Placebo

During the study either placebo or Rizatriptan will be given to subjects to take during the treatment phase of the study.

Sponsors & Collaborators

  • Robert W. Baloh

    lead OTHER

Principal Investigators

  • Robert W Baloh, M.D. · University of California, Los Angeles

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2020-07-31
Completion
2020-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02447991 on ClinicalTrials.gov